cyclohexanol has been researched along with Anxiety Neuroses in 138 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (9.42) | 18.2507 |
| 2000's | 97 (70.29) | 29.6817 |
| 2010's | 28 (20.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, L; Chen, J; Fang, Y; Hong, W; Peng, D; Wu, Z; Yuan, C; Zhang, C | 1 |
| Cooper, AJ; Lohoff, FW; Rickels, K | 1 |
| De Berardis, D; Di Giannantonio, M; Ferrara, M; Mazza, M; Moschetta, FS; Serroni, N; Tempesta, D | 1 |
| Cooper, AJ; Lohoff, FW; Narasimhan, S; Rickels, K | 1 |
| Barlow, DH; Brown, B; Brown, TA; Ciraulo, DA; Devine, E; Eisenmenger, K; Farchione, T; Gulliver, SB; Kamholz, BW; Knapp, CM; Morissette, SB | 1 |
| Etemad, B; Gallop, R; Lohoff, FW; Mandos, LA; Rickels, K; Rynn, MA | 1 |
| Namdari, B | 1 |
| Lohoff, FW; Narasimhan, S; Saung, WT | 1 |
| Choi, TK; Kim, B; Lee, MH; Lee, SH | 1 |
| Crits-Christoph, P; Gallop, R; Gibbons, MB; Markell, HM; Newman, MG; Rickels, K | 1 |
| Chen, CY; Hung, CI; Liu, CY; Wang, SJ; Yang, CH | 1 |
| Luther, JF; Rush, AJ; Sung, SC; Trivedi, MH; Wisniewski, SR | 1 |
| Allgulander, C; Nutt, D | 1 |
| Allgulander, C; Lecrubier, Y; Nutt, D; Peters, T; Wittchen, U | 1 |
| Allgulander, C; Ball, S; Detke, M; Erickson, J; Nutt, D; Russell, J; Spann, M; Walker, D | 1 |
| Barlow, DH; Brown, TA; Ciraulo, D; Devine, E; Duade, J; Farchione, T; Gulliver, SB; Kamholz, BW; Morissette, SB | 1 |
| Hardy-Baylé, MC; Passerieux, C | 1 |
| Il'ina, NA | 2 |
| Ash, P; Jacob, MK | 1 |
| Arnow, BA; Barkin, JL; Dowling, F; Klein, DN; Kocsis, JH; Leon, AC; Manber, R; Rothbaum, BO; Trivedi, MH; Wisniewski, SR | 1 |
| Dukes, E; Mychaskiw, M; Oster, G; Rejas, J; Sofrygin, O; Vera-Llonch, M | 1 |
| Baker, RA; Berman, RM; Carlson, BX; Eudicone, JM; Mankoski, R; Nelson, JC; Pikalov, A; Tran, QV | 1 |
| Edwards, TR; Hince, DA; Hood, SD; Kalk, N; Lenox-Smith, A; Lingford-Hughes, AR; Melichar, JK; Nutt, DJ; Taylor, LG | 1 |
| Boerner, RJ | 1 |
| Bujoreanu, IS; DeMaso, DR; Ibeziako, P | 1 |
| Baillés, E; Bargalló, N; Boget, T; Carreño, M; Donaire, A; Matrai, S; Pintor, L; Rumia, J; Setoain, X | 1 |
| Etemad, B; Gallop, RJ; Khalid-Khan, S; Lohoff, FW; Rickels, K; Rynn, MA | 1 |
| Baldinetti, F; Bandelow, B; Herman, B; Kasper, S; Mandel, FS; Nivoli, G; Petralia, A; Van Ameringen, M | 1 |
| Bhogale, GS; Nayak, R; Patil, NM | 1 |
| Baldwin, DS; Lyndon, G; Schweizer, E; Xu, Y | 1 |
| Crits-Christoph, P; Gallop, R; Gibbons, MB; Hamilton, JL; Newman, MG; Pastva, AM; Rickels, K; Ring-Kurtz, S | 1 |
| Aquino, TD; Hodge, R; Lohoff, FW; Narasimhan, S; Rickels, K | 1 |
| Aquino, TD; Etemad, B; Lohoff, FW; Multani, PK; Narasimhan, S; Rickels, K | 1 |
| Capua, AD; Castrogiovanni, A; Ciani, V; Lazzeri, L; Luisi, S; Pacchierotti, C; Pasquini, R; Petraglia, F | 1 |
| Knapp, LE; Miceli, JJ; Ramey, TS; Rickels, K; Shiovitz, TM; Weaver, JJ | 1 |
| Liu, MM; Shi, HS; Si, JJ; Sun, LL; Suo, L; Wu, P; Yang, CH; Yang, JL; Zhang, Y; Zhu, WL | 1 |
| Bailey, JE; Craig, K; Dawson, GR; Diaper, A; Dourish, CT; Nutt, DJ; Osman-Hicks, V; Rich, AS | 1 |
| Lohoff, FW; Narasimhan, S; Rickels, K | 1 |
| De Bleeker, E; De Nayer, A; Evrard, JL; Fossion, P; Geerts, S; Leyman, S; Linkowski, P; Mignon, A; Ruelens, L; Schittecatte, M; Van Eeckhoutte, I | 1 |
| Cantillon, M; Davidson, JR; Hackett, D; Haudiquet, V; Meoni, P | 1 |
| Argyropoulos, S; Hardy, J; Nutt, DJ | 1 |
| Frare, F; Perugi, G; Ruffolo, G; Toni, C; Torti, C | 1 |
| Hackett, D; Haudiquet, V; Mahé, V; Montgomery, SA | 1 |
| Allgulander, C; Hirschfeld, RM; Nutt, DJ | 1 |
| Thase, ME; Trivedi, M | 1 |
| Rickels, K; Rynn, M | 1 |
| Gorman, JM | 2 |
| Hackett, D; Haudiquet, V; Salinas, E | 1 |
| Falissard, B | 1 |
| Hackett, D; Meoni, P; Otto, MW; Pollack, MH; Simon, N | 1 |
| Gupta, S; Masand, PS | 1 |
| Aiso, JY; Gutierrez, MA; Stimmel, GL | 1 |
| Borgeat, F; Hättenschwiler, J; Khazaal, Y; Mattia, M; Stankovic, M; Zullino, DF | 1 |
| Lenox-Smith, AJ; Reynolds, A | 1 |
| Baudendistel, TE; Khurana, RN | 1 |
| Chakrabarti, S; Jhirwal, OP | 1 |
| Bharucha, A; Lenze, EJ; Mulsant, BH; Pollock, BG; Reynolds, CF; Shear, MK | 1 |
| Lenox-Smith, A | 2 |
| Lucassen, PL; olde Hartman, TC; van Rijswijk, E | 1 |
| Hackett, D; Lader, M; Meoni, P | 1 |
| Albano, D; Grothe, DR; Scheckner, B | 1 |
| Bystritsky, A; Kelsey, JE; Mangano, RM; Pollack, MH; Stein, MB | 1 |
| Boyer, P; Hackett, D; Mahé, V | 1 |
| Hackett, D; Lydiard, RB; Pitrosky, B; White, C | 1 |
| Andrews, G; Carter, R; Donnelly, M; Haby, MM; Heuzenroeder, L; Mihalopoulos, C; Rossell, R; Vos, T | 1 |
| Allgulander, C; Dahl, AA; Emilien, G; Lepola, U; Mangano, R; Sjödin, I; Zhang, J | 1 |
| Kaprinis, G; Kogeorgos, J; Nimatoudis, I; Theodoropoulou, S; Vidalis, A; Zissis, NP | 1 |
| Silverstone, PH | 1 |
| Guest, JF; Lenox-Smith, A; Russ, J | 1 |
| Addington, S; Dichter, GS; Freid, CM; Shelton, RC; Tomarken, AJ | 1 |
| Katzman, M | 1 |
| Cunha, A; Gazalle, FK; Kapczinski, F; Lima, MS; Schmitt, R; Souza, J | 1 |
| Baldwin, DS; Lader, M; Montgomery, SA; Nil, R | 1 |
| Lang, AE; Voon, V | 1 |
| Benattia, I; Graepel, J; Kroenke, K; Messina, N; Musgnung, J | 1 |
| Chen, WJ; Chu, PL; Lu, TC; Tsai, KC; Wu, CS | 1 |
| Thase, ME | 2 |
| Baca, E; Garcia-Calvo, C; Prieto, R; Roca, M | 1 |
| Hackett, D; Tedeschi, MA; Wan, GJ; Zhang, HF | 1 |
| Bahk, WM; Chae, JH; Jun, TY; Kim, TS; Pae, CU; Rhee, WI; Yoon, SJ | 1 |
| Kasper, S; Montgomery, SA; Pande, AC; Tobias, K; Zornberg, GL | 1 |
| Connor, KM; Davidson, JR; Payne, V | 1 |
| Bandelow, B | 1 |
| Christodoulou, C; Douzenis, A; Lykouras, L; Michopoulos, I | 1 |
| Gendron, A; McIntyre, A | 1 |
| Agogué, C; Bérard, A; Carceller, AM; Ferreira, E; Francoeur, D; Martin, BZ; St-André, M | 1 |
| Kunz, NR; Riddle, MA; Rynn, MA; Yeung, PP | 1 |
| Khazaal, Y | 1 |
| Sheehan, DV; Sheehan, KH | 1 |
| Colombo, C; De Ronchi, D; Mandelli, L; Rossini, D; Serretti, A; Tarricone, I; Zanardi, R | 1 |
| Ball, S; Detke, M; Dinkel, J; Dunayevich, E; Erickson, J; Hartford, J; Kornstein, S; Liebowitz, M; Pigott, T; Russell, J; Walker, D | 1 |
| Allgulander, C; Sheehan, DV | 1 |
| Connor, K; Davidson, JR; Vaishnavi, S | 1 |
| Heerdink, ER; van Dijk, L; Volkers, AC | 1 |
| Albano, AM; Entusah, AR; March, JS; Rynn, M; Tourian, KA | 1 |
| Black, JL; McAlpine, DE; Mrazek, DA; O'Kane, DJ | 1 |
| Ahmed, S; Haudiquet, V; Stahl, SM | 1 |
| Alexander, AL; Davidson, RJ; Johnstone, T; Kalin, NH; Nitschke, JB; Polis, S; Somerville, LH; Whalen, PJ | 1 |
| Bose, A; Gommoll, C; Korotzer, A; Li, D | 1 |
| Alpert, JE; Balasubramani, GK; Biggs, MM; Carmin, CN; Fava, M; Howland, R; Leuchter, A; Rush, AJ; Trivedi, MH; Warden, D; Wisniewski, SR; Zisook, S | 1 |
| Bakish, D; Ball, S; Duenas, H; Erickson, J; Hallberg, C; Nicolini, H; Russell, JM; Sagman, D; Spann, M | 1 |
| Altamura, AC; D'Urso, N; Dell'osso, B; Fumagalli, S; Mundo, E; Russo, M | 1 |
| Rothschild, AJ | 1 |
| Entsuah, R; Khan, A; Leventer, SM; Rudolph, RL; Upton, GV | 1 |
| Entsuah, AR; Feighner, JP; McPherson, MK | 1 |
| Chouinard, G; Dallal, A | 1 |
| Crawford, M; Emmanuel, N; Johnson, MR; Lydiard, RB; Villareal, G | 1 |
| Ravindran, A; Silverstone, PH | 1 |
| Bakish, D | 1 |
| Stahl, SM | 1 |
| Davidson, JR; DuPont, RL; Haskins, JT; Hedges, D | 1 |
| Judge, R; Wagner, BE | 1 |
| Ninan, PT | 1 |
| Sheehan, DV | 2 |
| Feighner, JP | 1 |
| Haskins, JT; Pollack, MH; Rickels, K; Sheehan, DV | 1 |
| Aguiar, L; Gelenberg, AJ; Haskins, JT; Lydiard, RB; Rudolph, RL; Salinas, E | 1 |
| Gunning, K; Magill, MK | 1 |
| Kalin, NH; Roseboom, PH | 1 |
| Kelsey, JE | 1 |
| Hackett, D | 1 |
| Allgulander, C; Hackett, D; Salinas, E | 1 |
| Salinas, E; Silverstone, PH | 1 |
| Ablon, JS; Bouffard, SM; Cohen, LS; Collins, MH; Morabito, C; Nonacs, RM; Viguera, AC | 1 |
| Ballenger, JC | 1 |
| Brault, Y; Hackett, D; Meoni, P; Salinas, E | 1 |
| Bandelow, B; Boerner, RJ; Linden, M; Riemann, D; Schwarzer, W; Wittchen, HU | 1 |
| Höfler, M; Hoyer, J; Krause, P; Wittchen, HU | 1 |
| Alexopoulos, GS; Hackett, D; Katz, IR; Reynolds, CF | 1 |
| Culpepper, L | 1 |
39 review(s) available for cyclohexanol and Anxiety Neuroses
| Article | Year |
|---|---|
[Mood disorders].
Topics: Adolescent; Adult; Age Factors; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; Bipolar Disorder; Cyclohexanols; Depressive Disorder; Diagnosis, Differential; Drug Therapy, Combination; Electroconvulsive Therapy; Female; Hospitalization; Humans; Male; Mood Disorders; Personality Disorders; Pregnancy; Prognosis; Psychotherapy; Psychotropic Drugs; Recurrence; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Suicide; Time Factors; Venlafaxine Hydrochloride; Young Adult | 2008 |
[Anxiety disorders: diagnosis and therapy from the family physician's perspective].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Behavior Therapy; Cognitive Behavioral Therapy; Cyclohexanols; Diagnosis, Differential; Family Practice; Humans; Panic Disorder; Paroxetine; Practice Guidelines as Topic; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2006 |
Psychiatric concerns in pediatric epilepsy.
Topics: Adolescent; Amines; Anxiety Disorders; Bipolar Disorder; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Cyclohexanols; Epilepsy; Gabapentin; gamma-Aminobutyric Acid; Humans; Mental Disorders; Norepinephrine; Pregabalin; Selective Serotonin Reuptake Inhibitors; Valproic Acid; Venlafaxine Hydrochloride; Young Adult | 2010 |
Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Venlafaxine: a new class of antidepressant.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Depressive Disorder; Humans; Venlafaxine Hydrochloride | 2002 |
Long-term treatment strategies in anxiety disorders.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Female; Humans; Male; Prevalence; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Time Factors; Venlafaxine Hydrochloride | 2002 |
Optimizing treatment outcomes for patients with depression and generalized anxiety disorder.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Humans; Paroxetine; Psychotherapy; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Pharmacotherapy of generalized anxiety disorder.
Topics: Algorithms; Alprazolam; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Combined Modality Therapy; Cyclohexanols; Delayed-Action Preparations; Drug Administration Schedule; Humans; Paroxetine; Psychotherapeutic Processes; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Treating generalized anxiety disorder.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Clinical Trials as Topic; Cognitive Behavioral Therapy; Cyclohexanols; Humans; Imipramine; Paroxetine; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; United States; Venlafaxine Hydrochloride | 2003 |
Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies.
Topics: Adolescent; Adult; Anxiety Disorders; Chi-Square Distribution; Confidence Intervals; Cyclohexanols; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2003 |
The safety of SSRIs in generalised anxiety disorder: any reason to be anxious?
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Buspirone; Clinical Trials as Topic; Cyclohexanols; Humans; Monoamine Oxidase Inhibitors; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Venlafaxine Hydrochloride | 2003 |
Venlafaxine: a 2003 update.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Humans; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2003 |
[Pharmacotherapy of generalized anxiety disorder: state of the art].
Topics: Adolescent; Adult; Age Factors; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Benzodiazepines; Child; Child, Preschool; Cyclohexanols; Double-Blind Method; Humans; Meta-Analysis as Topic; Paroxetine; Placebos; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Time Factors; Venlafaxine Hydrochloride | 2003 |
Treatment considerations for anxiety in the elderly.
Topics: Aged; Anxiety Disorders; Cognition Disorders; Cyclohexanols; Diagnosis, Differential; Humans; Panic Disorder; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Traumatic; Venlafaxine Hydrochloride | 2003 |
Treatment of pain syndromes with venlafaxine.
Topics: Analgesics; Animals; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Humans; Pain; Pain, Postoperative; Randomized Controlled Trials as Topic; Venlafaxine Hydrochloride | 2004 |
Impact of gastrointestinal symptom severity on response to venlafaxine extended-release in patients with generalized anxiety disorder.
Topics: Adult; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Male; Patient Dropouts; Placebos; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Australia; Cost-Benefit Analysis; Cyclohexanols; Disability Evaluation; Humans; Imipramine; Mental Health Services; Panic Disorder; Paroxetine; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Time Factors; Venlafaxine Hydrochloride | 2004 |
Qualitative review of SNRIs in anxiety.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Double-Blind Method; Humans; Norepinephrine; Placebos; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Serotonin; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Venlafaxine in the treatment of anxiety disorders.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Cyclohexanols; Humans; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis.
Topics: Antidepressive Agents; Anxiety Disorders; Cyclohexanols; Female; Humans; Imipramine; Male; Paroxetine; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Discontinuation symptoms in depression and anxiety disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cyclohexanols; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paroxetine; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Withholding Treatment | 2007 |
Managing depressive and anxiety disorders with escitalopram.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cyclohexanols; Depressive Disorder; Humans; Models, Economic; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Stereoisomerism; Venlafaxine Hydrochloride | 2006 |
Treatment of anxiety disorders with venlafaxine XR.
Topics: Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Humans; Product Surveillance, Postmarketing; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Defining response and remission in anxiety disorders: toward an integrated approach.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Humans; Personality Assessment; Personality Inventory; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Current approaches to the pharmacologic treatment of anxiety disorders.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Brain; Cyclohexanols; Drug Approval; Humans; Monoamine Oxidase Inhibitors; Receptors, Neurotransmitter; Selective Serotonin Reuptake Inhibitors; United States; United States Food and Drug Administration; Venlafaxine Hydrochloride | 2007 |
Generalized anxiety disorder: raising the expectations of treatment.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depression; Female; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2002 |
The diagnosis and treatment of late-life depression.
Topics: Age Factors; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Cyclohexanols; Depressive Disorder; Diagnosis, Differential; Electroconvulsive Therapy; Female; Humans; Lithium; Male; Monoamine Oxidase Inhibitors; Piperazines; Selective Serotonin Reuptake Inhibitors; Sex Factors; Trazodone; Triazoles; Venlafaxine Hydrochloride | 1996 |
The patient with comorbid depression and anxiety: the unmet need.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Clinical Trials as Topic; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Fluoxetine; Humans; Placebos; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
The functional anatomy, neurochemistry, and pharmacology of anxiety.
Topics: Adrenergic Uptake Inhibitors; Amygdala; Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Clomipramine; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Humans; Norepinephrine; Prefrontal Cortex; Selective Serotonin Reuptake Inhibitors; Serotonin; Venlafaxine Hydrochloride | 1999 |
Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder.
Topics: Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorders; Buspirone; Clinical Trials as Topic; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Humans; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride | 1999 |
Overview of antidepressants currently used to treat anxiety disorders.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Humans; Monoamine Oxidase Inhibitors; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1999 |
Neuropharmacology of venlafaxine.
Topics: Adenylyl Cyclases; Anxiety Disorders; Corticotropin-Releasing Hormone; Cyclohexanols; Electroencephalography; Humans; Locus Coeruleus; Raphe Nuclei; Receptors, Adrenergic, beta; Selective Serotonin Reuptake Inhibitors; Sleep, REM; Synaptic Transmission; Venlafaxine Hydrochloride | 2000 |
Venlafaxine XR in the treatment of anxiety.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Humans; Treatment Outcome; Venlafaxine Hydrochloride | 2000 |
Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Cyclohexanols; Drug Administration Schedule; gamma-Aminobutyric Acid; Humans; Monoamine Oxidase Inhibitors; Norepinephrine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Serotonin; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Clinical Trials as Topic; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Drug Administration Schedule; Humans; Patient Dropouts; Placebos; Psychiatric Status Rating Scales; Remission Induction; Survival Analysis; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Cyclohexanols; Delayed-Action Preparations; Drug Administration Schedule; Humans; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Female; Humans; Logistic Models; Male; Middle Aged; Randomized Controlled Trials as Topic; Venlafaxine Hydrochloride | 2002 |
Treatment of generalized anxiety disorder.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Clinical Trials as Topic; Cognitive Behavioral Therapy; Cyclohexanols; Follow-Up Studies; Humans; Paroxetine; Psychotherapy; Pyrimidines; Relaxation Therapy; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Generalized anxiety disorder in primary care: emerging issues in management and treatment.
Topics: Adaptation, Psychological; Adolescent; Adult; Anxiety Disorders; Cognitive Behavioral Therapy; Comorbidity; Cyclohexanols; Depressive Disorder; Female; Humans; Male; Middle Aged; Paroxetine; Physicians, Family; Prevalence; Primary Health Care; Recurrence; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; United States; Venlafaxine Hydrochloride | 2002 |
56 trial(s) available for cyclohexanol and Anxiety Neuroses
| Article | Year |
|---|---|
Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Buspirone; China; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Remission Induction; Risperidone; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2013 |
Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Double-Blind Method; Female; Genotype; Humans; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Receptors, Opioid, mu; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride; White People; Young Adult | 2013 |
Genetic polymorphisms in the PACAP and PAC1 receptor genes and treatment response to venlafaxine XR in generalized anxiety disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Drug Administration Schedule; Female; Genetic Variation; Genotype; Humans; Male; Neuropeptides; Pharmacogenetics; Pituitary Adenylate Cyclase-Activating Polypeptide; Polymorphism, Genetic; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Double-Blind Method; Female; Humans; Male; Medication Adherence; Relaxation Therapy; Venlafaxine Hydrochloride | 2013 |
Remission of generalized anxiety disorder after 6 months of open-label treatment with venlafaxine XR.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Female; Humans; Logistic Models; Male; Middle Aged; Neuroticism; Outcome Assessment, Health Care; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Time Factors; Venlafaxine Hydrochloride | 2013 |
Lack of influence of DAT1 and DRD2 gene variants on antidepressant response in generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Dopamine Plasma Membrane Transport Proteins; Double-Blind Method; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptors, Dopamine D2; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2014 |
Combined medication and CBT for generalized anxiety disorder with African American participants: reliability and validity of assessments and preliminary outcomes.
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Black or African American; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Double-Blind Method; Female; Humans; Male; Middle Aged; Reproducibility of Results; Surveys and Questionnaires; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Citalopram; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Outpatients; Predictive Value of Tests; Single-Blind Method; Sleep Initiation and Maintenance Disorders; Substance-Related Disorders; Surveys and Questionnaires; Treatment Outcome; United States; Venlafaxine Hydrochloride | 2015 |
Differences between daily smokers, chippers, and nonsmokers with co-occurring anxiety and alcohol-use disorders.
Topics: Adolescent; Adult; Aged; Alcohol-Related Disorders; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cognitive Behavioral Therapy; Cyclohexanols; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Middle Aged; Smoking; Venlafaxine Hydrochloride; Young Adult | 2008 |
Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies.
Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2010 |
Efficiency of venlafaxine in patients with psychogenic nonepileptic seizures and anxiety and/or depressive disorders.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Depressive Disorder; Electroencephalography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Psychiatric Status Rating Scales; Seizures; Statistics, Nonparametric; Venlafaxine Hydrochloride; Video Recording; Young Adult | 2010 |
Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release.
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Cyclohexanols; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Neurotransmitter Uptake Inhibitors; Norepinephrine; Patient Dropouts; Pregabalin; Psychiatric Status Rating Scales; Quality of Life; Selective Serotonin Reuptake Inhibitors; Time Factors; Venlafaxine Hydrochloride | 2009 |
Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
Topics: Adult; Analgesics; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; gamma-Aminobutyric Acid; Humans; Logistic Models; Male; Middle Aged; Predictive Value of Tests; Pregabalin; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2012 |
Combined medication and cognitive therapy for generalized anxiety disorder.
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride | 2011 |
Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Anxiety Disorders; Cyclohexanols; Double-Blind Method; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, Serotonin, 5-HT2; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2013 |
Use of venlafaxine in psychiatric disorders and climacteric syndrome: is a therapeutic bridge?
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Climacteric; Cyclohexanols; Drug Repositioning; Female; Humans; Mental Disorders; Middle Aged; Psychiatric Status Rating Scales; Research Design; Selective Serotonin Reuptake Inhibitors; Syndrome; Treatment Outcome; Venlafaxine Hydrochloride | 2012 |
Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Anxiety Disorders; Citalopram; Cyclohexanols; Double-Blind Method; Drug Therapy, Combination; Europe; Female; gamma-Aminobutyric Acid; Humans; Kaplan-Meier Estimate; Least-Squares Analysis; Linear Models; Male; Middle Aged; Odds Ratio; Paroxetine; Placebos; Pregabalin; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; United States; Venlafaxine Hydrochloride | 2012 |
Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic.
Topics: Administration, Inhalation; Adult; Anxiety Disorders; Blood Pressure; Carbon Dioxide; Cyclohexanols; Double-Blind Method; Female; gamma-Aminobutyric Acid; Heart Rate; Humans; Male; Panic; Pregabalin; Surveys and Questionnaires; Venlafaxine Hydrochloride; Young Adult | 2013 |
Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder.
Topics: Antidepressive Agents; Anxiety Disorders; Biomarkers, Pharmacological; Cyclohexanols; Double-Blind Method; Haplotypes; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT2A; Serotonin Plasma Membrane Transport Proteins; Venlafaxine Hydrochloride; White People | 2013 |
Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Belgium; Cyclohexanols; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Outpatients; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride | 2002 |
Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Dysthymic Disorder; Female; Humans; Male; Middle Aged; Outpatients; Prospective Studies; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Humans; Psychiatric Status Rating Scales; Survival Analysis; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Cyclohexanols; Diazepam; Dose-Response Relationship, Drug; Double-Blind Method; Female; GABA Modulators; Humans; Male; Middle Aged; Patient Dropouts; Personality Inventory; Placebo Effect; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2003 |
Statistical considerations about the question of a selection of discriminating centres in the analysis of clinical trial. In response to the paper: "A method for controlling for a high response rate in a comparison of venlafaxine XR and diazepan in the sh
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Bias; Cyclohexanols; Data Collection; Diazepam; Dose-Response Relationship, Drug; Double-Blind Method; Female; GABA Modulators; Humans; Male; Middle Aged; Placebo Effect; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2003 |
A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Primary Health Care; Quality of Life; Selective Serotonin Reuptake Inhibitors; United Kingdom; Venlafaxine Hydrochloride | 2003 |
Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Cyclohexanols; Double-Blind Method; Female; Humans; Male; Psychometrics; Somatoform Disorders; Venlafaxine Hydrochloride | 2004 |
Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.
Topics: Adult; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Outpatients; Patient Dropouts; Phobic Disorders; Psychiatric Status Rating Scales; Reproducibility of Results; Single-Blind Method; Suicide; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Social adjustment in generalised anxiety disorder: a long-term placebo-controlled study of venlafaxine extended release.
Topics: Adjustment Disorders; Adolescent; Adult; Aged; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Social Adjustment; Venlafaxine Hydrochloride | 2004 |
Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Control Groups; Cyclohexanols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Phobic Disorders; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Greece; Humans; Male; Outpatients; Psychiatric Status Rating Scales; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Do venlafaxine XR and paroxetine equally influence negative and positive affect?
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Personality Assessment; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Antidepressant treatment outcomes of psychogenic movement disorder.
Topics: Adult; Ambulatory Care; Anxiety Disorders; Chronic Disease; Citalopram; Combined Modality Therapy; Comorbidity; Conversion Disorder; Cyclohexanols; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Hypochondriasis; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Somatoform Disorders; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.
Topics: Ambulatory Care; Anxiety Disorders; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Health Status; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pilot Projects; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Somatoform Disorders; Surveys and Questionnaires; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Drug Administration Schedule; Female; Headache; Humans; Male; Middle Aged; Nausea; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sweating; Venlafaxine Hydrochloride; Weight Gain | 2006 |
Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.
Topics: Adult; Anticonvulsants; Anxiety Disorders; Cyclohexanols; Disorders of Excessive Somnolence; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Placebos; Pregabalin; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Kava in generalized anxiety disorder: three placebo-controlled trials.
Topics: Anxiety Disorders; Cyclohexanols; Double-Blind Method; Female; Humans; Kava; Male; Middle Aged; Phytotherapy; Plant Preparations; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2006 |
Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Dibenzothiazepines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Personality Inventory; Quetiapine Fumarate; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2007 |
Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials.
Topics: Adolescent; Age Factors; Ambulatory Care; Anxiety Disorders; Child; Cyclohexanols; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Endpoint Determination; Humans; Meta-Analysis as Topic; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial.
Topics: Adult; Anxiety Disorders; Cyclohexanols; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Personality Inventory; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
A Randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; Confidence Intervals; Cyclohexanols; Double-Blind Method; Female; Humans; Male; Pediatrics; Psychiatric Status Rating Scales; Regression Analysis; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER.
Topics: Adult; Anxiety Disorders; Cyclohexanols; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Selective Serotonin Reuptake Inhibitors; Somatoform Disorders; Venlafaxine Hydrochloride | 2007 |
A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder.
Topics: Adult; Amygdala; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Facial Expression; Fear; Female; Gyrus Cinguli; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Pattern Recognition, Visual; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cyclohexanols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Personality Assessment; Personality Inventory; Psychometrics; Treatment Outcome; United States; Venlafaxine Hydrochloride; Young Adult | 2008 |
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents; Anxiety Disorders; Citalopram; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Prospective Studies; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Somatoform Disorders; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial.
Topics: Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Psychophysiologic Disorders; Psychotherapy; Surveys and Questionnaires; Thiophenes; Venlafaxine Hydrochloride; Young Adult | 2009 |
The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Depressive Disorder; Dizziness; Double-Blind Method; Female; Humans; Male; Nausea; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1998 |
Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cohort Studies; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 1998 |
Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Recurrence; Substance Withdrawal Syndrome; Treatment Outcome; Venlafaxine Hydrochloride | 1998 |
Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Middle Aged; Placebos; Prospective Studies; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
Topics: Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorders; Buspirone; Cyclohexanols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Placebos; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Placebos; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2000 |
Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Outpatients; Psychiatric Status Rating Scales; Severity of Illness Index; Venlafaxine Hydrochloride | 2000 |
Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxiety Disorders; Chronic Disease; Cyclohexanols; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride | 2001 |
Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
Topics: Adult; Anxiety Disorders; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Placebos; Prospective Studies; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Cyclohexanols; Delayed-Action Preparations; Drug Administration Schedule; Humans; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
44 other study(ies) available for cyclohexanol and Anxiety Neuroses
| Article | Year |
|---|---|
Neuropsychological functioning in young subjects with generalized anxiety disorder with and without pharmacotherapy.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Attention; Case-Control Studies; Citalopram; Cyclohexanols; Executive Function; Female; Humans; Male; Memory; Neuropsychological Tests; Venlafaxine Hydrochloride | 2013 |
Venlafaxine abuse in a patient with schizophrenia and prior history of substance dependence: a case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Drug-Seeking Behavior; Humans; Male; Middle Aged; Schizophrenia; Schizophrenic Psychology; Substance-Related Disorders; Venlafaxine Hydrochloride | 2013 |
Long-standing depression and anxiety in a Korean woman.
Topics: Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Republic of Korea; Venlafaxine Hydrochloride | 2014 |
The impacts of migraine and anxiety disorders on painful physical symptoms among patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Analgesics; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Disease Management; Female; Humans; Male; Middle Aged; Migraine Disorders; Pain; Pain Measurement; Symptom Assessment; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2014 |
Wine and drug evaluations: lessons on making comparisons of noninferiority.
Topics: Anxiety Disorders; Cross-Cultural Comparison; Cyclohexanols; Depressive Disorder; Drug Approval; Duloxetine Hydrochloride; Europe; Humans; Placebo Effect; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome; United States; United States Food and Drug Administration; Venlafaxine Hydrochloride; Wine | 2008 |
Establishing non-inferiority in treatment trials in psychiatry: guidelines from an Expert Consensus Meeting.
Topics: Antidepressive Agents; Anxiety Disorders; Consensus Development Conferences as Topic; Cyclohexanols; Duloxetine Hydrochloride; Evidence-Based Medicine; Humans; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Thiophenes; Venlafaxine Hydrochloride | 2008 |
A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Cyclohexanols; Data Interpretation, Statistical; Delayed-Action Preparations; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Thiophenes; Venlafaxine Hydrochloride | 2008 |
Experience of the use of velaxin (venlafaxine) in anxious depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Depression; Female; Humans; Inpatients; Male; Middle Aged; Outpatients; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Venlafaxine-induced complex visual hallucinations in a 17-year-old boy.
Topics: Adolescent; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Hallucinations; Humans; Male; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2009 |
Early adversity in chronic depression: clinical correlates and response to pharmacotherapy.
Topics: Adolescent; Adult; Age of Onset; Aged; Algorithms; Antidepressive Agents; Anxiety Disorders; Bupropion; Child; Child Abuse, Sexual; Chronic Disease; Citalopram; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Life Change Events; Male; Mianserin; Middle Aged; Mirtazapine; Parenting; Risk Factors; Self Concept; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2009 |
Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective.
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Anxiety Disorders; Confidence Intervals; Cost-Benefit Analysis; Cyclohexanols; Delayed-Action Preparations; Economics, Pharmaceutical; gamma-Aminobutyric Acid; Humans; Models, Economic; Models, Statistical; Monte Carlo Method; Pregabalin; Psychiatric Status Rating Scales; Psychometrics; Quality-Adjusted Life Years; Spain; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Noradrenergic function in generalized anxiety disorder: impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Anxiety Disorders; Blood Pressure; Clonidine; Cyclohexanols; Eye Movements; Female; Heart Rate; Human Growth Hormone; Humans; Hydrocortisone; Male; Middle Aged; Neuropsychological Tests; Norepinephrine; Receptors, Adrenergic; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2011 |
Venlafaxine and excessive yawning: is there any link?
Topics: Adult; Anxiety Disorders; Cyclohexanols; Humans; Male; Venlafaxine Hydrochloride; Yawning | 2011 |
Association analysis between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and treatment response to venlafaxine XR in generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Anxiety Disorders; Brain-Derived Neurotrophic Factor; Cyclohexanols; Diagnostic and Statistical Manual of Mental Disorders; Female; Genetic Variation; Genotype; Humans; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride; White People; Young Adult | 2011 |
Venlafaxine facilitates between-session extinction and prevents reinstatement of auditory-cue conditioned fear.
Topics: Acoustic Stimulation; Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Conditioning, Psychological; Cues; Cyclohexanols; Disease Models, Animal; Dose-Response Relationship, Drug; Extinction, Psychological; Fear; Male; Motor Activity; Rats; Rats, Sprague-Dawley; Time Factors; Venlafaxine Hydrochloride | 2012 |
Hypertensive crisis associated with venlafaxine.
Topics: Adult; Alcohol Deterrents; Alcoholism; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Depression; Disulfiram; Drug Interactions; Humans; Hypertension; Venlafaxine Hydrochloride | 2003 |
Venlafaxine withdrawal in organic anxiety disorder.
Topics: Adult; Anxiety Disorders; Cyclohexanols; Female; Humans; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 2003 |
Response to 'Wishful pharmaceutical thinking'.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Humans; Remission Induction; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Wishful pharmaceutical thinking.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Humans; Psychiatric Status Rating Scales; Research Design; Venlafaxine Hydrochloride | 2003 |
Value in venlafaxine study.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Humans; Periodicals as Topic; Venlafaxine Hydrochloride | 2004 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; Drug Therapy; Fluoxetine; Humans; Paroxetine; Patient Satisfaction; Primary Health Care; Psychiatry; Psychology; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Sertraline; Social Work | 2004 |
[Vital functions at risk. Dealing with depressions rapidly and comprehensively].
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Cyclohexanols; Depressive Disorder; HIV Infections; Humans; Long-Term Care; Randomized Controlled Trials as Topic; Sick Role; Venlafaxine Hydrochloride | 2004 |
Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cost-Benefit Analysis; Cyclohexanols; Diazepam; Economics, Pharmaceutical; Humans; State Medicine; United Kingdom; Venlafaxine Hydrochloride | 2005 |
Neuroleptic malignant syndrome after the use of venlafaxine in a patient with generalized anxiety disorder.
Topics: Aged; Anxiety Disorders; Cyclohexanols; Humans; Male; Neuroleptic Malignant Syndrome; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2006 |
Venlafaxine extended-release in patients older than 80 years with depressive syndrome.
Topics: Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Female; Humans; Male; Primary Health Care; Prospective Studies; Remission Induction; Spain; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Estimation of symptom-free days in generalized anxiety disorder.
Topics: Adult; Anxiety Disorders; Chi-Square Distribution; Cyclohexanols; Double-Blind Method; Europe; Female; Humans; Male; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Statistics, Nonparametric; Treatment Outcome; United States; Venlafaxine Hydrochloride | 2006 |
Topiramate use in alprazolam addiction.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Female; Fructose; Humans; Substance Withdrawal Syndrome; Substance-Related Disorders; Topiramate; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Depressive Disorder; Female; Humans; Infant Behavior; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Male; Pregnancy; Pregnancy Complications; Pregnancy Trimester, Third; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2007 |
Mania after venlafaxine withdrawal in a patient with generalized anxiety disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Bipolar Disorder; Cyclohexanols; Humans; Male; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 2007 |
Antidepressant response in the elderly.
Topics: Adult; Age Factors; Aged; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials.
Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Kava; Mianserin; Mirtazapine; Paroxetine; Psychometrics; Sertraline; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2007 |
Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005).
Topics: Adolescent; Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Child; Cyclohexanols; Depressive Disorder; Drug Labeling; Drug Prescriptions; Drug Utilization; Family Practice; Female; Humans; Imipramine; Male; Netherlands; Nocturnal Enuresis; Paroxetine; Practice Patterns, Physicians'; Selective Serotonin Reuptake Inhibitors; Tension-Type Headache; Time Factors; Venlafaxine Hydrochloride | 2007 |
Cytochrome P450 2D6 genotype variation and venlafaxine dosage.
Topics: Adolescent; Adult; Alleles; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Cytochrome P-450 CYP2D6; Delayed-Action Preparations; Depressive Disorder, Major; Dysthymic Disorder; Female; Genotype; Humans; Male; Middle Aged; Retrospective Studies; Treatment Failure; Venlafaxine Hydrochloride | 2007 |
[Velaxin (venlafaxine) in the treatment of anxious depression].
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Depression; Female; Humans; Inpatients; Male; Middle Aged; Outpatients; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder.
Topics: Antidepressive Agents; Anxiety Disorders; Cyclohexanols; Demography; Diagnostic and Statistical Manual of Mental Disorders; Disease Progression; Female; Humans; Male; Middle Aged; Severity of Illness Index; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
Treatment of generalized anxiety disorder with venlafaxine: a series of 11 cases.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Personality Inventory; Treatment Outcome; Venlafaxine Hydrochloride | 1998 |
Mergers and acquisitions among psychotropics: antidepressant takeover of anxiety may now be complete.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Drug Approval; Humans; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1999 |
Once-daily venlafaxine XR compared with fluoxetine in outpatients with depression and anxiety.
Topics: Anxiety Disorders; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Fluoxetine; Humans; Neurotransmitter Uptake Inhibitors; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
Generalized anxiety disorder in family practice patients.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Cyclohexanols; Depression; Diagnosis, Differential; Family Practice; Humans; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; United States; Venlafaxine Hydrochloride | 2000 |
Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder.
Topics: Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Drug Tolerance; Humans; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2000 |
Venlafaxine in the treatment of postpartum depression.
Topics: Adult; Anxiety Disorders; Cyclohexanols; Depression, Postpartum; Depressive Disorder; Drug Administration Schedule; Female; Humans; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
Venlafaxine and generalised anxiety disorder: new preparation. Minimise recourse to drugs.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Benzodiazepines; Clinical Trials as Topic; Cyclohexanols; Delayed-Action Preparations; Drug Interactions; France; Humans; Treatment Outcome | 2001 |
[Generalized anxiety disorders (GAD)--a neglected illness? Background und aims of the GAD-P study].
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Diagnosis, Differential; Humans; Middle Aged; Prevalence; Primary Health Care; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2001 |
[Family physician's interventions and prescribing practice. Results of the GAD-P study].
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; Barbiturates; Behavior Therapy; Cyclohexanols; Depression; Female; Humans; Hypnotics and Sedatives; Male; Physicians, Family; Phytotherapy; Referral and Consultation; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2001 |